Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the fifteen ratings firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $156.50.
Several brokerages have recently issued reports on ABVX. Citigroup reissued an “outperform” rating on shares of Abivax in a research report on Tuesday, June 2nd. Guggenheim restated a “buy” rating on shares of Abivax in a report on Tuesday, June 30th. Morgan Stanley restated an “overweight” rating and issued a $180.00 price objective on shares of Abivax in a report on Friday, July 24th. HC Wainwright restated a “buy” rating on shares of Abivax in a report on Tuesday, June 30th. Finally, Wolfe Research set a $136.00 price objective on shares of Abivax in a research report on Wednesday, June 3rd.
Get Our Latest Research Report on ABVX
Abivax Stock Up 3.7%
Abivax (NASDAQ:ABVX – Get Free Report) last released its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The firm had revenue of $1.56 million during the quarter, compared to the consensus estimate of $0.40 million. On average, research analysts anticipate that Abivax will post -3.22 EPS for the current fiscal year.
Institutional Investors Weigh In On Abivax
A number of institutional investors have recently made changes to their positions in ABVX. Versant Capital Management Inc bought a new position in shares of Abivax during the second quarter worth approximately $30,000. GHP Investment Advisors Inc. lifted its holdings in Abivax by 155.6% during the 1st quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock worth $26,000 after purchasing an additional 140 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in Abivax by 661.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock valued at $53,000 after purchasing an additional 344 shares during the period. T. Rowe Price Investment Management Inc. bought a new stake in Abivax in the 4th quarter valued at $61,000. Finally, WPG Advisers LLC grew its holdings in Abivax by 125.9% in the 4th quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after buying an additional 253 shares in the last quarter. Institutional investors own 47.91% of the company’s stock.
Abivax Company Profile
Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.
Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.
Featured Stories
- Five stocks we like better than Abivax
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.
